Human Immunology News Volume 2.39 | Oct 14 2014

    0
    42

    Human Immunology News 2.39 October 14, 2014

    Human Immunology News

         In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  HIN on Twitter

     
    TOP STORY
    Single Gene Links Susceptibility to Rare Infections with Predisposition to Autoimmune Disease
    In previous research, investigators linked a lack of ISG15 to an unusual vulnerability to infections by mycobacteria, a group of common bacteria that include the TB bug. Using cells from patients, they found that when they restored the ISG15 gene, the cells became able to resolve inflammation. [Press release from The Rockefeller University discussing online prepublication in Nature] Press Release | Abstract
    View Data: UM729, a Novel Small Molecule for Ex Vivo Expansion of Human hSCs

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    C-Type Lectin-Like Receptor LOX-1 Promotes Dendritic Cell-Mediated Class-Switched B Cell Responses
    The authors report that lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) expressed on dendritic cells and B cells promotes humoral responses. On B cells LOX-1 signaling upregulated CCR7, promoting cellular migration toward lymphoid tissues. [Immunity] Abstract

    Human TLR10 Is an Anti-Inflammatory Pattern-Recognition Receptor
    The authors demonstrate that Toll-like receptor (TLR)10 is a modulatory receptor with mainly inhibitory effects. Blocking TLR10 by antagonistic antibodies enhanced proinflammatory cytokine production, including IL-1β, specifically after exposure to TLR2 ligands. [Proc Natl Acad Sci USA] Abstract

    Central Domain of IL-33 Is Cleaved by Mast Cell Proteases for Potent Activation of Group-2 Innate Lymphoid Cells
    Researchers investigated the role of mast cells known to interact with group-2 innate lymphoid cells (ILC2s) in vivo. They found that serine proteases secreted by activated mast cells generate mature forms of interleukin-33 (IL-33) with potent activity on ILC2s. [Proc Natl Acad Sci USA] Abstract

    MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer that Is Reversed by Interferon and Selumetinib Treatment In Vitro
    Researchers evaluated major histocompatibility complex (MHC) class I expression on papillary thyroid cancer (PTC) and analyzed changes in MHC expression and associated immune activation with current and experimental treatments for thyroid cancer using in vitro PTC cell lines. Functional changes in antigenicity were assessed by co-culture of allogeneic donor peripheral blood leukocytes with pre-treated or untreated PTC cell lines and measurement of T cell activation and cytokine production. [Clin Cancer Res] Abstract

    First-in-Man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread and Anti-Tumor Activity
    Investigators performed the first-in-human Phase I, intratumoral dose escalation clinical trial of the Western Reserve strain of vaccinia virus engineered for tumor selectivity through two targeted gene deletions (vvDD) in 16 patients with advanced solid tumors. In addition to safety, they evaluated signs of vvDD replication and spread to distant tumors, pharmacokinetics and pharmacodynamics, clinical and immune responses to vvDD. [Mol Ther] Abstract

    Coordinated Regulation of NK Receptor Expression in the Maturing Human Immune System
    Using mass cytometry, scientists found that natural killer cell receptor (NKR) expression patterns distinguish cell lineages in human peripheral blood. Mature NK and CD8+ T cell populations show increased diversity of NKR surface expression patterns, but with distinct determinants. [J Immunol] Abstract

    Genetic Polymorphisms and Tissue Expression of Interleukin-22 Associated with Risk and Therapeutic Response of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
    Investigators explored the genetic predisposition to mucosa-associated lymphoid tissue lymphoma and its clinical implication. In vitro experiments demonstrate that co-culturing peripheral mononuclear cells or CD4+ T cells with Helicobacter pylori stimulated the secretion of interleukin-22 (IL-22), and that IL-22 induced the expression of antimicrobial proteins, RegIIIα and lipocalin-2, in gastric epithelial cells. [Blood Cancer J]
    Full Article

    Cellular Immunologic Responses to Cochlear Implantation in the Human
    Histologic evidence of a foreign body reaction has been described in temporal bones in patients who in life had undergone cochlear implantation. The cellular immune response was characterized using immunohistochemical stains for B-cell lymphocytes, T-cell lymphocytes, and macrophages. [Hear Res] Abstract

    Subscribe to our sister publications:
    Immunology of Infectious Disease News and Immune Regulation News
    !

    25% Off First Order: MNCs, purified cells and more! Expires October 31st, 2014

     
    REVIEWS
    IRAK Signaling in Cancer
    In some malignancies, dysregulation of inflammatory toll-like receptor (TLR) and interleukin-1 receptor (IL1R) signaling is typified by increased NF-κB activity, and it occurs through somatic mutations, chromosomal deletions, and/or transcriptional deregulation. Interleukin-1 receptor-associated kinase (IRAK) family members are mediators of TLR/IL1R superfamily signaling, and mounting evidence implicates these kinases as viable cancer targets. [Br J Cancer] Full Article

    Translational Research in Oncology – 10 Years of Progress and Future Prospects
    The authors review selected developments in translational cancer biology, diagnostics, and therapeutics that have occurred over the past decade and offer our thoughts on future prospects for the next few years.
    [Nat Rev Clin Oncol]
    Abstract

    Visit our reviews page to see a complete list of reviews in the human immunology research field.

     
    SCIENCE NEWS
    Amgen Announces Positive Top-Line Results From Phase III Study Evaluating the Efficacy and Safety of Biosimilar Candidate ABP 501 Compared with Adalimumab in Patients with Moderate-to-Severe Plaque Psoriasis
    Amgen announced its Phase III study evaluating efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe plaque psoriasis met its primary endpoint. [Amgen Inc.] Press Release

    From our sponsor: Learn how ex vivo models drive progress in HIV research. Read the research profiles.

     
    INDUSTRY NEWS
    Johns Hopkins Pediatrician Wins NIH Transformative Research Award
    Johns Hopkins Children’s Center infectious disease specialist Sanjay Jain, M.D., has earned a Transformative Research Award from the National Institutes of Health (NIH) for his ongoing work to design a new noninvasive imaging method that can rapidly identify a wide variety of bacterial infections and monitor their response to treatment in real time. [Johns Hopkins University] Press Release

    Dynavax Initiates Phase I/II Study of TLR-9 Agonist Immunotherapy in B-Cell Lymphoma
    Dynavax Technologies Corporation announced initiation of a Phase I/II clinical trial to assess the safety and preliminary efficacy of SD-101, an investigational Toll-like receptor (TLR) 9 agonist, in adults with untreated low-grade B-cell lymphoma. [Dynavax Technologies Corporation] Press Release

    University of Maryland School of Medicine and Malian Ministry of Health Begin Human Trials of Experimental Ebola Vaccine in Mali, West Africa
    The Center for Vaccine Development in conjunction with its sister institution, The Center for Vaccine Development of Mali and the Ministry of Health of Mali, have begun a clinical trial in health care workers (and other front-line workers) to evaluate a promising experimental Ebola vaccine. [University of Maryland School of Medicine] Press Release

    VGTI Florida Launches the Center for Diseases of Aging to Develop Innovative Treatments for a Broad Range of Difficult-to-Treat Diseases
    The Vaccine & Gene Therapy Institute of Florida (VGTI Florida) announced the launch of its Center for Diseases of Aging, a major initiative to accelerate the discovery and advancement of novel, best-in-class healthcare interventions for the prevention and treatment of diseases commonly associated with aging. [Vaccine & Gene Therapy Institute of Florida] Press Release

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW Immune Homeostasis and Inflammatory Disease: A Herrenhausen Symposium
    November 6-8, 2014
    Hanover, Germany

    NEW Cell Symposia: The Multifaceted Roles of Type 2 Immunity
    December 10-12, 2014
    Bruges, Belgium

    Visit our events page to see a complete list of events in the human immunology community.

     
    JOB OPPORTUNITIES
    NEW Professorship Position – Virology (Medical University of Vienna)

    NEW PhD Position – Childhood Respiratory Virus Infections and Development of Asthma (Norwegian University of Science and Technology)

    Faculty Positions – Immunology (Nanjing Medical University)

    Senior Research Fellow – Immunosenescence and Immune Exhaustion in Persistent Infections and Aging (Singapore Immunology Network A*STAR)

    Postdoctoral Fellow – Interleukin 23 in the Pathogenesis of Systemic Lupus Erythematosus (Beth Israel Medical Center)

    Research Scientist – Immunology (Beijing Genomics Institute)

    Postdoctoral Fellowship – Immunology (Huazhong University of Science and Technology)

    Postdoctoral Position – Transplantation Aspects of Hepatocytes Derived from Human Pluripotent Stem Cells (INSERM UMR 1064 )

    Postdoctoral Position – Human Mucosal Immunology (INSERM)

    Scientist – Recombinant Molecules and Antibodies (STEMCELL Technologies Inc.)

    Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

    Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

    Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

    Research Associate – Cell Separation (STEMCELL Technologies Inc.)


    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Human Immunology News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Human Immunology News: Archives | Events | Contact Us